PRESS RELEASE published on 03/14/2023 at 22:40, 1 year 7 months ago Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
PRESS RELEASE published on 03/10/2023 at 17:00, 1 year 7 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 1 year 8 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 1 year 8 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 1 year 8 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 1 year 8 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
PRESS RELEASE published on 02/17/2023 at 17:00, 1 year 8 months ago Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
PRESS RELEASE published on 02/16/2023 at 22:05, 1 year 8 months ago Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
PRESS RELEASE published on 02/02/2023 at 13:00, 1 year 9 months ago Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
PRESS RELEASE published on 01/30/2023 at 13:15, 1 year 9 months ago Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published on 11/08/2024 at 15:00, 1 hour 1 minute ago Hoverfly Technologies Promotes Steve Topping to Chief Operating Officer
Published on 11/08/2024 at 15:00, 1 hour 1 minute ago The Biltmore Los Angeles Welcomes Matthias Kaiser as New General Manager
Published on 11/08/2024 at 15:00, 1 hour 1 minute ago SustainableIT.org Joins COP29 To Champion Climate Solutions and Responsible AI in Baku, Azerbaijan
Published on 11/08/2024 at 15:00, 1 hour 1 minute ago Sky Gold Hires Gaia Life Capital Inc for Media Services
Published on 11/08/2024 at 15:46, 15 minutes ago Original-Research: Koenig & Bauer AG (von Montega AG): Kaufen (zuvor: Halten)
Published on 11/08/2024 at 15:13, 47 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/08/2024 at 15:12, 48 minutes ago Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Published on 11/08/2024 at 12:32, 3 hours 28 minutes ago Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Published on 11/08/2024 at 12:32, 3 hours 28 minutes ago Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Published on 11/08/2024 at 12:15, 3 hours 46 minutes ago Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Published on 11/08/2024 at 12:15, 3 hours 46 minutes ago Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Published on 11/08/2024 at 08:00, 8 hours 1 minute ago DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
